KISSEI PHARMACEUTICAL CO.,LTD. Logo

KISSEI PHARMACEUTICAL CO.,LTD.

Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.

4547 | T

Overview

Corporate Details

ISIN(s):
JP3240600001
LEI:
Country:
Japan
Address:
松本市芳野19番48号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kissei Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company strategically focuses its research and development efforts on specific therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its business model integrates in-house drug discovery with strategic partnerships, such as in-licensing and out-licensing agreements, to build a robust product pipeline. Kissei's portfolio comprises both specialty and generic drugs, aiming to address unmet medical needs and contribute to the health of people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:34
Interim Report
確認書
Japanese 8.9 KB
2025-11-10 08:33
Interim Report
半期報告書-第81期(2025/04/01-2026/03/31)
Japanese 236.4 KB
2025-06-27 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 23.3 KB
2025-06-24 06:01
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 06:01
Governance Information
内部統制報告書-第80期(2024/04/01-2025/03/31)
Japanese 25.5 KB
2025-06-24 06:00
Annual Report
有価証券報告書-第80期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2025-06-11 06:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2024-12-27 08:00
Major Shareholding Notification
大量保有報告書
Japanese 38.5 KB
2024-12-13 05:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-11-13 05:01
Interim Report
確認書
Japanese 9.0 KB
2024-11-13 05:00
Interim Report
半期報告書-第80期(2024/04/01-2025/03/31)
Japanese 240.5 KB
2024-06-28 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 29.4 KB
2024-06-25 06:01
Governance Information
内部統制報告書-第79期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-25 06:00
Registration Form
確認書
Japanese 9.0 KB
2024-06-25 06:00
Registration Form
有価証券報告書-第79期(2023/04/01-2024/03/31)
Japanese 1.5 MB

Automate Your Workflow. Get a real-time feed of all KISSEI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KISSEI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KISSEI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America
AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America
AMGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.